Frequently Asked Questions

What are the symptoms of Parkinson’s disease?

Signs may include:¹

Tremors, or involuntary shaking, in hands, arms, legs, head or jaw
Stiffness or contracting of the muscles that may cause pain or limit your range of motion
Slowed movement, called bradykinesia, when walking, getting up out of a chair, etc.
Impaired balance and coordination, sometimes leading to falls
Stooped or slumped posture
Difficulty with speech, handwriting
Challenges to unconscious movements like blinking, smiling, swinging of the arms when walking

1. Source: https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/symptoms-causes/syc-20376055

Who may be a good candidate to apply for this study?

You or a loved one should consider applying for the study if you:

Are at least 30 years old
Have a confirmed diagnosis of Parkinson’s disease (PD)
Experience clearly defined ON, OFF, and dyskinetic periods throughout the day where PD medication is either managing symptoms or waning
Have been on a stable dose of PD medication for at least 30 days; MAO-B inhibitors (such as selegiline, rasagiline, safinamide) must be stable for at least 12 weeks
Are able to freely move about, with or without assistive device

Are there any costs to participate in this study?

No, there is no cost to participate. Qualified participants will receive all study-related care and study medication at no cost, and compensation for time and travel may be available.

Are there any risks to participating?

As all drugs and medical procedures carry a risk of side effects, the possibility that participants may experience some discomfort or other reactions does exist. The study staff will explain these potential risks before participants decide whether to participate, and address any concerns.

What are the benefits of participating?

The information gathered in this study may help identify new treatment options in the future for people living with advanced Parkinson’s disease. Study participants will be connected to specialists who understand their situation and can help answer questions and address concerns. It is our goal that participants will enjoy a safe, professional environment, be treated with kindness and respect, and have access to top quality clinical care throughout the trial.

What is being researched in the trial?

The purpose of this study is to measure the effects of CVN424 (Solengepras) in Parkinson’s Disease (PD) participants experiencing motor fluctuations and dyskinesia. The investigational treatment, CVN424 (Solengepras), targets a receptor in the brain that is overactive in PD and believed to contribute to the sensations of stiffness, slowness, unsteadiness, and shaking that many people experience. Researchers in this clinical trial are studying whether CVN424 (Solengepras) can potentially reduce that overactivity, and potentially improve the amount of good ON time vs. OFF time that PD patients experience.

What will happen during the trial?

This is a randomized, double-blind study, which means neither participants nor study staff will not know whether participants receive CVN424 or a placebo, which contains no active medication. Participants will be asked to visit the study site throughout the trial, which consists of a 6-week pre-screening period, 12-week treatment period, and 2-week follow-up. These scheduled visits may include physical exams, vital signs, blood sampling, questionnaires, electrocardiograms, and/or neurological testing. Participants who successfully complete this study and retain eligibility will be invited to participate in a future open-label extension (OLE) study, should they choose it.

What is the likelihood that I receive the placebo?

The probability that a participant will receive the placebo is 33%.

Does qualifying ensure my participation in the study?

Before a potential participant decides whether to take part in the study, the study staff will review the informed consent form with them and answer any questions. Once the consent form has been signed by the participant, the screening period of the study begins. During this period, the staff will review medical history and conduct any relevant assessments. All participants who meet all of the study criteria will be invited to participate.

Can I change my mind about participating in the study?

Participation is entirely voluntary. Even if you are already involved in the study, you can change your mind at any time for any reason.

What if I have more questions?

If you are interested in learning more, please contact us at any time. You may email us at help@clinicalenrollment.com.

See If You Qualify